Market Place
Sourcing Support
Plus Therapeutics to Announce Q3 Results & Host Call on Nov 14
05 Nov 2024 //
GLOBENEWSWIRE
Plus Therapeutics Showcases Leptomeningeal Programs at SNO 2024
29 Oct 2024 //
GLOBENEWSWIRE
Plus Therapeutics Updates ReSPECT-GBM Trial at Neurosurgeons Meeting
01 Oct 2024 //
GLOBENEWSWIRE
Plus Therapeutics Presents ReSPECT-GBM Data At CNS Meeting
18 Sep 2024 //
GLOBENEWSWIRE
Plus Therapeutics To Present At H.C. Wainwright Conference
04 Sep 2024 //
GLOBENEWSWIRE
Plus Therapeutics Reports Q2 2024 Financial Results And Business Highlights
14 Aug 2024 //
GLOBENEWSWIRE
Plus Therapeutics Presents Trial Results At SNO/ASCO Conference
13 Aug 2024 //
GLOBENEWSWIRE
Plus Therapeutics Presents ReSPECT-LM Phase 1 Data At SNO/ASCO
12 Aug 2024 //
GLOBENEWSWIRE
Plus Therapeutics To Announce Q2 Results On August 14, 2024
08 Aug 2024 //
GLOBENEWSWIRE
Plus Therapeutics Presents Leptomeningeal Metastases Data At SNO/ASCO
25 Jul 2024 //
GLOBENEWSWIRE
Plus Therapeutics To Present At Gordon Research Conference
02 Jul 2024 //
GLOBENEWSWIRE
Plus Expands Management, Reports $3.3M CPRIT Payment
06 Jun 2024 //
GLOBENEWSWIRE
Plus Therapeutics Announces New Employment Inducement Grants
17 May 2024 //
GLOBENEWSWIRE
Plus Therapeutics Reports Q1 2024 Results, Business Highlights
15 May 2024 //
GLOBENEWSWIRE
Plus Therapeutics To Announce Q1 Results, Host Call On May 15
13 May 2024 //
GLOBENEWSWIRE
Plus Therapeutics LM Acquisition, FORESEE Trial Topline Data
09 May 2024 //
GLOBENEWSWIRE
Plus Therapeutics Investor Call On Acquisition, FORESEE Data
08 May 2024 //
GLOBENEWSWIRE
Plus Therapeutics Announces Private Placement Financing of up to $18 Million
06 May 2024 //
GLOBENEWSWIRE
Plus Therapeutics Gets $3M DoD Award Recommendation
22 Apr 2024 //
GLOBENEWSWIRE
Plus Thera to Present at the National Comprehensive Cancer Network Conference
27 Mar 2024 //
GLOBENEWSWIRE
Plus Announces Validation & Clinical Implementation of CSF-01
25 Mar 2024 //
GLOBENEWSWIRE
Plus Therapeutics Completes Dosing in Phase 1 Trial of Rhenium
11 Mar 2024 //
GLOBENEWSWIRE
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
05 Mar 2024 //
GLOBENEWSWIRE
Plus Updates Financial and Cash Guidance for 2024
18 Dec 2023 //
GLOBENEWSWIRE
Plus Therapeutics Partners With K2bio for Development of Tests for Tumor Cell
12 Dec 2023 //
GLOBENEWSWIRE
Plus Therapeutics to Present at 5th Targeted Radiopharmaceuticals Summit Europe
29 Nov 2023 //
GLOBENEWSWIRE
Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data
20 Nov 2023 //
GLOBENEWSWIRE
Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data
15 Nov 2023 //
GLOBENEWSWIRE
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium Obisbemeda
03 Nov 2023 //
GLOBENEWSWIRE
Plus Therapeutics Reports Third Quarter 2023 Financial Results
31 Oct 2023 //
GLOBENEWSWIRE
Plus Therapeutics Announces Share Repurchase Program
31 Oct 2023 //
GLOBENEWSWIRE
Plus Therapeutics to Present at the Society for NeuroOncology Annual Meeting
25 Oct 2023 //
GLOBENEWSWIRE
Plus Therapeutics to Announce Third Quarter 2023 Financial Results
23 Oct 2023 //
GLOBENEWSWIRE
Plus Therapeutics Completes Dosing in Phase 1 Clinical Trial of Rhenium
10 Oct 2023 //
GLOBENEWSWIRE
Plus Therapeutics to Participate in the Jones Trading Healthcare Summit
09 Oct 2023 //
GLOBENEWSWIRE
Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT
11 Sep 2023 //
GLOBENEWSWIRE
Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics
08 Sep 2023 //
BUSINESSWIRE
Plus Enters into License for Cerebrospinal Fluid Tumor Cell Enumeration Assay
08 Sep 2023 //
GLOBENEWSWIRE
Plus Therapeutics Initiates Phase 1/2a Trial for Leptomeningeal Metastase
05 Sep 2023 //
GLOBENEWSWIRE
Plus Therapeutics to Present at the H.C. Wainwright 25th Conference
30 Aug 2023 //
GLOBENEWSWIRE
Plus Therapeutics Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Plus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at Cancer Conference
11 Aug 2023 //
GLOBENEWSWIRE
Plus Therapeutics Announces Leader Roundtable on Trial Data Being Presented
08 Aug 2023 //
GLOBENEWSWIRE
Plus Therapeutics to Announce Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Plus Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference
03 Aug 2023 //
GLOBENEWSWIRE
Plus Therapeutics to Present at the 2023 SNO/ASCO CNS Cancer Conference
27 Jul 2023 //
GLOBENEWSWIRE
Plus Therapeutics Appointed Pius Maliakal as VP of Clinical Operations
27 Jul 2023 //
GLOBENEWSWIRE
Plus Therapeutics to Present at 2nd Annual Targeted Radiopharmaceuticals Summit
13 Jul 2023 //
GLOBENEWSWIRE
Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT
29 Jun 2023 //
GLOBENEWSWIRE
Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference
14 Jun 2023 //
GLOBENEWSWIRE
Plus Therapeutics Announces Participation at SNO Pediatric Conference
08 Jun 2023 //
GLOBENEWSWIRE
Plus Therapeutics Provides Company Update Today
01 Jun 2023 //
GLOBENEWSWIRE
Plus Therapeutics Announces Topline Results from Glioblastoma at ASCO 2023
30 May 2023 //
GLOBENEWSWIRE
Plus Therapeutics to Present at the 2023 Virtual June Investor Summit
25 May 2023 //
GLOBENEWSWIRE
Plus Therapeutics Regains Compliance with Nasdaq Listing Requirements
16 May 2023 //
GLOBENEWSWIRE
Plus Therapeutics to Present in EndBrainCancer Initiative Educational Event
12 May 2023 //
GLOBENEWSWIRE
Plus Therapeutics, Piramal Pharma Expand Partnership for cGMP Drug Production
05 May 2023 //
CONTRACT PHARMA
Plus Therapeutics Reports 1Q 2023 FYR and Business Highlights
20 Apr 2023 //
GLOBENEWSWIRE
Plus Therapeutics Completes Enrollment of the Original Three Patients
19 Apr 2023 //
GLOBENEWSWIRE
Plus Therapeutics Completes Phase 1/Part A of the ReSPECT-LM Clinical Trial
18 Apr 2023 //
GLOBENEWSWIRE
